Clinical Report: GPOEM for Delayed Gastric Conduit Emptying
Overview
This prospective, two-center investigation evaluated gastric peroral endoscopic myotomy (GPOEM) for refractory delayed gastric conduit emptying (DGCE) after esophagectomy and examined potential predictors of clinical response. The supplied article excerpt describes the study rationale, eligibility, and procedures but does not provide treatment outcomes, adverse events, or predictor results.
Background
DGCE can follow esophagectomy with gastric conduit reconstruction, in part because vagal nerve injury may contribute to pylorospasm and impaired antral motility. The source reports that approximately 15–50% of patients develop symptoms including abdominal pain, nausea, early satiety, heartburn, and regurgitation, which may impair quality of life. Dietary modification and prokinetic therapy are commonly used initially, while refractory symptoms may prompt pylorus-directed endoscopic or surgical treatment. Evidence specifically evaluating GPOEM in patients with gastric conduit reconstruction after esophagectomy is described as limited.
Data Highlights
Study feature
Details reported in the supplied excerpt
Design and setting
Prospective investigation at Utrecht University Medical Center and Amsterdam University Medical Center, Netherlands
Enrollment period
March 2021 through December 2024
Eligibility
Adults with refractory DGCE symptoms beginning more than 3 months after esophagectomy, plus at least one objective finding
Objective findings accepted
Impaired gastric emptying scintigraphy or timed barium swallow; retained solid food in the conduit at gastroscopy; or symptomatic improvement lasting at least 2 months after pyloric botulinum toxin injection
Follow-up
Endoscopy at 3 and 12 months after GPOEM
Postprocedure care
At least one night in hospital; oral intake withheld for 24 hours, followed by liquid and semi-solid diets for 7 days each
Outcomes
Not included in the supplied excerpt
Key Findings
The study was designed to assess the efficacy and safety of GPOEM in patients with DGCE after esophagectomy and to examine potential predictors of response.
Enrollment took place at two academic medical centers in the Netherlands from March 2021 through December 2024.
Eligible patients had refractory symptoms beginning more than 3 months after surgery and at least one specified objective finding supporting DGCE.
Patients with alternative causes of DGCE, prior pyloric surgery, any previous or attempted GPOEM, or uncontrolled coagulopathy were excluded.
EndoFLIP was used to measure pyloric minimum cross-sectional area and balloon pressure; distensibility was calculated as minimum cross-sectional area divided by balloon pressure.
The supplied excerpt does not report clinical response rates, safety outcomes, or which factors predicted response; the related-article context likewise provides background rather than results applicable to this study.
Clinical Implications
The excerpt describes a prospective evaluation of GPOEM in a selected group with refractory post-esophagectomy DGCE, using objective evidence of impaired emptying or prior response to pyloric botulinum toxin as part of eligibility. It does not provide outcome data or predictor results, so no treatment-effect estimate or patient-selection recommendation can be drawn from the supplied material.
Conclusion
The study addresses a clinical evidence gap concerning GPOEM for refractory DGCE after esophagectomy. Its efficacy, safety, and predictors of response cannot be summarized from the excerpt provided because the results are absent.
